NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-9.24%)
USD 0.49
(-9.24%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.74 Million USD | 34.25% |
| 2022 | 2.04 Million USD | 270.42% |
| 2021 | 551 Thousand USD | 9.54% |
| 2020 | 503 Thousand USD | -87.57% |
| 2019 | 4.04 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 1.65 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 106 Thousand USD | -77.78% |
| 2009 | 477 Thousand USD | -46.1% |
| 2008 | 885 Thousand USD | 10.35% |
| 2007 | 802 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2 Million USD | -17.05% |
| 2024 Q1 | 2.42 Million USD | -11.57% |
| 2023 Q1 | 1.97 Million USD | -3.09% |
| 2023 Q3 | 2.99 Million USD | -1.35% |
| 2023 Q2 | 3.04 Million USD | 53.69% |
| 2023 Q4 | 2.74 Million USD | -8.64% |
| 2023 FY | 2.74 Million USD | 34.25% |
| 2022 Q2 | 2.27 Million USD | -4.9% |
| 2022 Q3 | 2.15 Million USD | -4.93% |
| 2022 FY | 2.04 Million USD | 270.42% |
| 2022 Q4 | 2.04 Million USD | -5.42% |
| 2022 Q1 | 2.38 Million USD | 333.21% |
| 2021 Q4 | 551 Thousand USD | 181.12% |
| 2021 FY | 551 Thousand USD | 9.54% |
| 2021 Q1 | 405 Thousand USD | -19.48% |
| 2021 Q2 | 303 Thousand USD | -25.19% |
| 2021 Q3 | 196 Thousand USD | -35.31% |
| 2020 FY | 503 Thousand USD | -87.57% |
| 2020 Q3 | 701 Thousand USD | -51.45% |
| 2020 Q2 | 1.44 Million USD | -57.33% |
| 2020 Q1 | 3.38 Million USD | -16.36% |
| 2020 Q4 | 503 Thousand USD | -28.25% |
| 2019 FY | 4.04 Million USD | 0.0% |
| 2019 Q1 | 3.26 Million USD | 0.0% |
| 2019 Q2 | 4.71 Million USD | 44.37% |
| 2019 Q3 | 4.73 Million USD | 0.25% |
| 2019 Q4 | 4.04 Million USD | -14.46% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | 3.06 Million USD | 85.08% |
| 2016 Q2 | 524 Thousand USD | -82.89% |
| 2016 Q3 | - USD | -100.0% |
| 2016 FY | - USD | -100.0% |
| 2015 FY | 1.65 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | 1.65 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | -100.0% |
| 2011 FY | - USD | -100.0% |
| 2011 Q1 | 42 Thousand USD | -60.38% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q1 | 372 Thousand USD | -22.01% |
| 2010 Q2 | 271 Thousand USD | -27.15% |
| 2010 Q3 | 168 Thousand USD | -38.01% |
| 2010 Q4 | 106 Thousand USD | -36.9% |
| 2010 FY | 106 Thousand USD | -77.78% |
| 2009 Q2 | 687 Thousand USD | -12.71% |
| 2009 FY | 477 Thousand USD | -46.1% |
| 2009 Q1 | 787 Thousand USD | -11.07% |
| 2009 Q3 | 583 Thousand USD | -15.14% |
| 2009 Q4 | 477 Thousand USD | -18.18% |
| 2008 FY | 885 Thousand USD | 10.35% |
| 2008 Q1 | 931 Thousand USD | 16.08% |
| 2008 Q2 | 1.07 Million USD | 15.47% |
| 2008 Q3 | 980 Thousand USD | -8.84% |
| 2008 Q4 | 885 Thousand USD | -9.69% |
| 2007 Q3 | 543 Thousand USD | -6.7% |
| 2007 Q1 | 111 Thousand USD | 0.0% |
| 2007 FY | 802 Thousand USD | 0.0% |
| 2007 Q4 | 802 Thousand USD | 47.7% |
| 2007 Q2 | 582 Thousand USD | 424.32% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -453.535% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -900.0% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 97.724% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -29.673% |
| Azitra, Inc. | 885.94 Thousand USD | -209.274% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -6750.171% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -115.972% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 62.134% |
| CEL-SCI Corporation | 13.57 Million USD | 79.811% |
| iBio, Inc. | 4.46 Million USD | 38.565% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 7.182% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 22.947% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | -12.558% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -776.231% |
| BiomX Inc. | 15.09 Million USD | 81.845% |
| BiomX Inc. | 15.09 Million USD | 81.845% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 89.574% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -364.141% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 80.487% |